Literature DB >> 35510369

Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2.

Rohan Ameratunga1,2,3, See-Tarn Woon2,3, Richard Steele2,4, Klaus Lehnert5,6, Euphemia Leung6,7, Anna E S Brooks5,6.   

Abstract

INTRODUCTION: COVID-19 has had a calamitous impact on the global community. Apart from at least 6 M deaths, hundreds of millions have been infected and a much greater number have been plunged into poverty. Vaccines have been effective but financial and logistical challenges have hampered their rapid global deployment. Vaccine disparities have allowed the emergence of new SARS-CoV-2 variants including delta and omicron, perpetuating the pandemic. AREAS COVERED: The immunological response to SARS-CoV-2 is now better understood. Many of the clinical manifestations of severe disease are a consequence of immune dysregulation triggered by the virus. This may explain the lack of efficacy of antiviral treatments, such as convalescent plasma infusions, given later in the disease. EXPERT OPINION: T cells play a crucial role in both the outcome of COVID-19 as well as the protective response to vaccines. Vaccines do not prevent infection but reduce the risk of a chaotic and destructive cellular immune response to the virus. Severe COVID-19 should be considered a virus-induced secondary immune dysregulatory disorder of cellular immunity, with broad host susceptibility. This perspective of COVID-19 will lead to better diagnostic tests, vaccines, and therapeutic strategies in the future.

Entities:  

Keywords:  COVID-19; Omicron; SARS-CoV2; Vaccines; immunodeficiency; plasma therapy

Mesh:

Substances:

Year:  2022        PMID: 35510369     DOI: 10.1080/1744666X.2022.2074403

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   5.124


  1 in total

1.  SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?

Authors:  Rohan Ameratunga; Euphemia Leung; See-Tarn Woon; Lydia Chan; Richard Steele; Klaus Lehnert; Hilary Longhurst
Journal:  J Allergy Clin Immunol Pract       Date:  2022-06-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.